Matrix metalloproteinases (MMPs) are calcium-dependent zinc containing endopeptidases responsible for the degradation of most of extracellular matrix proteins during organogenesis, growth and normal tissue turnover. MMPs play a role in almost every biological cell process from embryo implantation to cell death and have been implicated in a wide range of diseases including inflammation, arthritis, pulmonary disease, cancer and more.
PerkinElmer’s MMPSense NIR activatable fluorescence agents are designed to evaluate many disease related processes including cancer progression, rheumatoid arthritis, pulmonary disease and more as well as evaluating therapeutic efficacy of potential drug candidates.
For laboratory use only. This product is intended for animal research only and not for use in humans.
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
MMPSense 750 FAST is excited by 749 nm excitation light, and emits at 775 nm. MMPSense 750 FAST is a member of a family of activatable fluorescent imaging agents comprising a novel architecture termed F.A.S.T. (Fluorescent Activatable Sensor Technology), that allows for an earlier optimal imaging window of 12-24 hours after injection, facilitating detection of MMP activity changes in acute models of inflammation or stroke. In addition, the 750 nm wavelength is optimal for minimizing the impact of autofluorescence and chow-related fluorescence that can interfere with image quality. Including MMPSense 750 FAST in careful experimental design allows for multiplexing with other channels and/or imaging times, and so can be paired with other probes to achieve maximum efficiency and flexibility in imaging.
|Fluorescent Agent Type||Activatable|
|Optical Imaging Classification||Fluorescence Imaging|
|Product Brand Name||MMPSense|
|Quantity in a Package Amount||1.0 Units|
|Shipping Condition||Blue Ice|
|Therapeutic Area||Atherosclerosis, Arthritis, Inflammation, Oncology/Cancer|
|Unit Size||1 Vial (10 doses)|
|Wave Length||750 nm|
MMPSense 750 FAST is the first in a family of activatable fluorescent imaging agents comprising a novel architecture termed F.A.S.T. (Fluorescent Activatable Sensor Technology), that confers an improved pharmacokinetic profile with earlier imaging time points. This architecture offers higher target specific signal with reduced background while also reducing the optimal imaging time after injection.
MMPSense 750 FAST activatable fluorescent imaging agent protocol
Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And our hard-earned expertise makes us a trusted provider of pre-clinical imaging solutions— with more than 9,000 peer reviewed articles as proof.
Cancer chemotherapy can produce severe side effects such as suppression of immune function and damage to heart muscle, gastrointestinal tract, and liver. If serious enough, tissue injury can be a major reason for late stage termination of drug discovery research projects, so it is becoming more important to integrate safety/toxicology assessments earlier in the drug development process. There are a variety of traditional serum markers, tailored mechanistically to specific tissues, however there are no current non-invasive assessment tools that are capable of looking broadly at in situ biological changes in target and non-target tissue induced by chemical insult.
The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.